FBIO achieved a dramatic turnaround from a $46.0M net loss to $6.8M net income while significantly strengthening its balance sheet through what appears to be the $205M sale of Cyprium's priority review voucher.
This represents a fundamental transformation in the company's financial position, with the PRV sale likely driving the massive improvement in profitability and balance sheet strength. The divestiture of Checkpoint Therapeutics and removal of Fred Hutchinson Cancer Center as a partner suggests strategic portfolio rationalization, though this reduces the company's subsidiary base.
FBIO experienced a remarkable financial turnaround with net income swinging from -$46.0M to +$6.8M, while cash increased 38.6% to $79.4M and stockholders' equity more than doubled to $49.9M. The 191% surge in accounts receivable to $29.8M and 30% reduction in current liabilities indicate strong cash generation and debt reduction, likely driven by the $205M PRV sale. Despite higher interest expense, the overall financial picture shows a company that has successfully monetized assets and dramatically improved its capital structure.
Receivables surged 191.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Equity base grew 119.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Net income grew 114.8% — bottom-line growth signals improving overall business health.
Interest expense surged 58.8% — significant debt increase or rising rates materially impacting earnings.
Cash position surged 38.6% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 37% — improving short-term liquidity or inventory/receivables build.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Inventory drawn down 33.3% — strong sell-through or deliberate destocking; watch for supply constraints.
Current liabilities reduced — improved short-term financial position and working capital health.
Asset base grew 28.7% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →